The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
#stockmarket #breaking
FDA approves standalone use of J&J’s ketamine-derived depression treatment – CNN
